We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+1.35%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$676M
AUM Growth
-$34.3M
Cap. Flow
+$13.8M
Cap. Flow %
2.04%
Top 10 Hldgs %
86.63%
Holding
24
New
2
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
CABO icon
Cable One
CABO
+$40.8M
2
BPMC
Blueprint Medicines
BPMC
+$4.99M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.01M
4
SIBN icon
SI-BONE Inc
SIBN
+$19

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$14.9M
2
XLRN
Acceleron Pharma
XLRN
+$9.75M
3
VYNE icon
VYNE Therapeutics
VYNE
+$5.23M
4
C icon
Citigroup
C
+$2.73M
5
COGT icon
Cogent Biosciences
COGT
+$408K

Sector Composition

Rank Sector Weight
1 Healthcare 86.98%
2 Communication Services 6.53%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$174M
$338M 50.08%
3,549,320
– –
GKOS icon
2
Glaukos
GKOS
$8.83B
$47.4M 7.02%
605,266
– –
CABO icon
3
Cable One
CABO
$245M
$44.2M 6.53%
+45,000
New +$40.8M
KIDS icon
4
OrthoPediatrics
KIDS
$511M
$29M 4.28%
654,549
– –
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$25.4M 3.76%
1,867,870
– –
AKBA icon
6
Akebia Therapeutics
AKBA
$335M
$25.4M 3.76%
3,100,000
– –
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$21.4M 3.17%
450,714
– –
SPNE
8
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$19.7M 2.92%
1,308,037
– –
CRVS icon
9
Corvus Pharmaceuticals
CRVS
$1.1B
$17.8M 2.63%
4,420,516
– –
SIBN icon
10
SI-BONE Inc
SIBN
$795M
$16.8M 2.49%
892,685
+1
+0% +$19
ETTX
11
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$14.7M 2.18%
2,181,843
– –
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$11.5M 1.7%
97,481
+10,000
+11% +$1.01M
NBRV
13
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$11.5M 1.7%
18,815
– –
INSP icon
14
Inspire Medical Systems
INSP
$1.5B
$9.94M 1.47%
175,000
– –
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$9.23M 1.37%
198,261
-222,032
-53% -$9.75M
STIM icon
16
Neuronetics
STIM
$126M
$8.01M 1.18%
525,000
– –
MRUS
17
DELISTED
Merus
MRUS
$7.43M 1.1%
502,795
– –
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$5.41M 0.8%
+67,567
New +$4.99M
VRNA
19
DELISTED
Verona Pharma
VRNA
$4.82M 0.71%
740,740
– –
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.07M 0.45%
135,009
– –
DERM
21
DELISTED
Dermira, Inc.
DERM
$2.72M 0.4%
201,059
-1,792,687
-90% -$14.9M
COGT icon
22
Cogent Biosciences
COGT
$6.79B
$2.08M 0.31%
118,360
-23,898
-17% -$408K
C icon
23
Citigroup
C
$221B
– –
-52,500
Closed -$2.73M
VYNE icon
24
VYNE Therapeutics
VYNE
$19.1M
– –
-353
Closed -$5.23M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2019 Portfolio in Review

As of Q1 2019, Novo Holdings A/S held 24 positions worth $676M, down 4.8% from $710M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Novo Holdings A/S's Q1 2019 filing shows 2 new, 2 increased, 3 reduced and 2 closed positions. Its largest new stake was Cable One: 45,000 shares worth $44.2M. The largest sale was Dermira, Inc., an estimated $14.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 92% a quarter earlier, followed by Communication Services and Financials.

  • Novo Holdings A/S's largest Q1 2019 buy was Cable One: 45,000 shares worth $44.2M.
  • Novo Holdings A/S added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2019, an estimated $1.01M increase.
  • Novo Holdings A/S's biggest Q1 2019 reduction was Dermira, Inc., cutting an estimated $14.9M.
  • Novo Holdings A/S fully exited VYNE Therapeutics in Q1 2019, selling an estimated $5.23M.
  • Novo Holdings A/S's ten largest holdings make up 87% of its $676M portfolio in Q1 2019.
  • Novo Holdings A/S opened 2 new positions and closed 2 in Q1 2019.
  • Novo Holdings A/S's portfolio value fell 4.8% quarter-over-quarter to $676M.

Based on Novo Holdings A/S's 13F filing for Q1 2019, filed 15 May 2019.